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ABSTRACT PRESENTATIONS
INITIAL EXPERIENCE WITH DOUBLE-NUCLEOSIDE
THERAPY FOR THE TREATMENT OF HIV INFECTION
IN PREGNANT WOMEN: SAFETY PROFILES IN WOMEN
AND NEWBORNS. NS Silverman MD;MM DiVito RN, MSN; D
Robbins MSN, CRNP. Division of MFM, Jefferson Medical Col-
lege of Thomas Jefferson Univ., Phila. PA.
Objective: While treatment regimens combining two or three an-
tiretrovirals have become standard for HIV-infected adults, con-
cerns over perinatal safety have limited the widespread use of
agents other than zidovudine (AZT) in pregnant women. While it
has been suggested that maternal or neonatal side effects with
newer nucleoside agents may not be significantly different from
those reported in large-scale trials with AZT alone during preg-
nancy, no objective data from human pregnancies are available. We
present our preliminary data from a policy offering AZT to all
pregnant women, with the intent of decreasing vertical transmission
in accordance with established guidelines, but that also offers a
second nucleoside agent for maternal therapy, in accordance with
current adult HIV protocols.
Study Design: Beginning in 1996, HIV-infected ,women at our
institution received extensive individual counseling and were of-
fered therapy with both AZT and a second nucleoside if they were
either AZT-non-naive or had abnormal lymphocyte subset profiles
at diagnosis. Hematologic, chemistry, and lymphocyte profiles
were followed through their pregnancies, with blood counts and
liver function testing performed on all newborns.
Results: From May 1996 to the present, nine women treated with
double-nucleoside therapy have delivered; another two pregnancies
are ongoing. AZT therapy (200 mg TID) was instituted or contin-
ued in women according to current guidelines at a median gesta-
tional age (GA) of 14 weeks (range 7-25), with two women already
on therapy when pregnancy was diagnosed. A second nucleoside
agent was prescribed in this cohort at a median GA of 24 weeks
(range 14-37): two women early in the study period received di-
danosine (ddI), 250 mg BID; the others were treated with lamivu-
dine (3TC), 150 mg BID. No patients stopped therapy for side
effects and none had significant changes in hematologic or liver-
function values from baseline to delivery. All patients delivered at
term (mean GA 38.7 _
1.1 wks), with a mean birthweight of 3182
+_ 620 gms. In the newborns, 4/9 had mild anemia (HCT<50%),
with a mean Hgb of 14.3 _+ 4.7 grrddl and Hct of 46 _+ 8.8%" their
mean white blood cell and platelet counts were normal. No new-
borns required blood transfusions, and all were discharged with
their mothers after normal exams in the nursery. Elevated transmi-
nases were seen in 7/9 newborns (mean SGOT 56 _+ 16 IU/1, SGPT
19 _+ 9 IU/1), but none required therapy for hyperbilirubinemia.
Conclusions: Our experience with double-nucleoside therapy in
this limited cohort of HIV-infected women provides early, objec-
tive support to its use during pregnancy for maternal indications.
Effects on maternal and neonatal clinical status and lab profiles
were comparable to those reported with AZT alone, and overall
acceptance and tolerance were high.
[-CHEMOKINE LEVELS IN PLASMA AND CERVICO-
VAGINAL LAVAGE (CVL) SPECIMENS FROM HIV1-
INFECTED AND UNINFECTED WOMEN. Antonio Sison,
Marek Jasinski, Michael Sp’ence, Joan Smith, Christian Hoffman,
Danuta Kozbor
Objective: The [3-chemokines MIP-lo, MIP-1 [3 and RANTES
have been shown to inhibit infection of CD4+ T cells by macro-
phage-tropic (M-tropic) HIV strains by blocking the [3-chemokine
receptor, CC-CKR-5, which is the principal cofactor for entry of
M-tropic HIV isolatesf. Individuals who show resistance to sexual
transmission of HIV1 have T cells that cannot be infected in vitro
by M-tropic HIV , presumably because high endogenous levels of
[3-chemokines may block entry and infection. However, the site of
action of these cytokines (vagina vs blood) has been poorly de-
scribed. Our aim was to measure levels of [3-chemokine production
in plasma and CVL from infected and uninfected women to assess
any protective role that these [3-chemokines play in both sexual and
perinatal transmission of virus.
Study Design: The cervicovaginal area of 18 asymptomatic HIV1-
infected and 2 uninfected patients was lavaged with 10 mls of
RPMI-1640. Heparinized plasma and aliquots of the CVL samples
were then tested for levels of [3-chemokines by quantitative ELISA,
and reported as 9g/ml.
Results: (Standard deviations are given with each mean.)
Patients
with RANTES
positive
signals CVL
MIP-Ic MIP-II3
PLASMA CVL PLASMA CVL
HIV+
(n 18) 6 3 2 6 4
Mean
(ng/ml) 524+968 392+295 984+279 202+121 194+ 144
HIV-
(n 2) 2 0 0 0
Increased levels of [3-chemokines were detected in 9 out of 18 CVL
samples from infected women. One patient who recently serocon-
verted had increased levels in all 3 chemokines. Seven of 18 in-
fected patients had high levels of MIP-lo and MIP-1 [3 in plasma.
Importantly, no correlation was found when comparing levels of
[3-chemokines in the plasma and CVL.
Conclusions: 1) [3-chemokines were detected in CVL in about half
of HIV-infected women and 40% in plasma, but high levels in CVL
did not correlate to those in plasma, suggesting an independent
chemokine activity in these compartments, and 2) recent serocon-
version may be associated with high [3-chemokine activity. Studies
are in progress to evaluate the effectiveness of sexual transmission
among those patients with elevated [3-chemokine levels.
q)eng et 1. Nature’1996;3’81166i"Pxton et al., Nature Med 996;
2:412.
TGF-B GENE EXPRESSION IN INFECTED GESTA-
TIONAL TISSUES: IMPLICATIONS FOR THE BALANCE
BETWEEN PRO- AND ANTI-INFLAMMATORY CYTO-
KINES. Leonid L. Reznikov, M.D. Ph.D. 1, Ronald S. Gibbs,
M.D. 1, Robert S. McDuffie, M.D.2, Joan Eskens M.S. , Kimberly
K. Leslie, M.D. Department of Obstetrics and Gynecology, the
University of Colorado Health Sciences Center and Kaiser Perma-
nente2, Denver, CO
Objectives: In the rabbit model of chorioamnionitis and infection-
induced preterm pregnancy loss, we have shown that amniotic fluid
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TNF-o rises significantly with infection; however, the protein con-
centration and bioactivity of the anti-inflammatory cytokine TGF-[3
do not change. We speculate that rising TNF-o in the face of
unchanging TGF-[3 creates an imbalance between pro- and anti-
inflammatory cytokines which favors prostaglandin production. We
now report an analysis of TGF-[3 gene expression in control versus
infected pregnant uterine tissues. The goal of these studies is to
determine whether mRNA levels correlate with TGF- protein lev-
els and bioactivity.
Study Design: New Zealand white rabbits at 70% gestation under-
went hysteroscopic inoculation of 105 cfu E. coli or saline (placebo)
and were sacrificed 16 h later. Total RNA was isolated and reverse
transcribed (RT). cDNA fragments for TGF-[3 1, TGF-[3 2, and
[3-actin were amplified by the the polymerase chain reaction (PCR),
and the products were run on ethidium bromide-stained agarose
gels. The specific bands for each amplified fragment were analyzed
by densitometer, and the relative expressions of TGF-[3 and 2
were determined compared to [3-actin for infected and control ani-
mals. The results were semi-quantitative, and expressed as the per-
cent of densitometric units of TGF-[3 compared to [3-actin.
Results: No gross differences in TGF-[3 or 2 mRNA levels were
detected by semi-quantitative RT-PCR analysis of the decidua and
full-thickness uterine wall in infected pregnant rabbits versus con-
trois.
Conclusion: Consistent with our previous measurements of TGF-[3
protein concentrations and bioactivity in the amniotic fluid of in-
fected versus control pregnant rabbits, our analysis of TGF-[3 gene
expression demonstrates no significant induction of TGF-[3 mes-
sages with infection. The lack of compensatory rise in TGF-[3 with
infection in our pregnant model suggests that TGF-[3 gene tran-
scription is differentially regulated compared to other infectious
and inflammatory conditions, where TGF-[3 expression is signifi-
cantly up-regulated.
CERVICOVAGINAL CYTOKINES IN PREGNANT
WOMEN WITH BACTERIAL VAGINOSIS AND FOR
TRICHOMONIASIS. Begona Martinez de Tejada, Sharon L.
Hillier, Dan V. Landers, Department of Obstetrics, Gynecology,
and Reproductive Sciences, University of Pittsburgh and Magee-
Womens Research Institute, Pittsburgh, PA.
Objectives: To evaluate the association between cervicovaginal
interleukin [3 (IL-1 ), interleukin 8 (IL-8), and interleukin 6 (IL-6)
with bacterial vaginosis (BV) and trichomoniasis.
Study Design: Cross-sectional study of 311 women at less than 20
completed weeks’ gestation. BV was defined as pH >4.5 and Gram
stain score > 7 (Nugent criteria). Trichomoniasis (TV) was diag-
nosed by broth culture.
Results: The median levels of the three cytokines stratified by
infection is shown below.
Cytokine (median pg/ml)
Infection N IL-113 IL-6 IL-8
BV + TV+ 14 5240* 516 62,108"
BV + TV- 116 4407* 320 13,726*
BV TV+ 12 7682* 345 52,687*
BV TV- 169 1532 370 19,390
*P < 0.05 Mann-Whitney U Test
Pregnant women with either TV or BV have significantly increased
concentrations of IL-1 comparedto uninfected women. IL-8 was
significantly increased in women with TV, and significantly de-
creased in women with BV, compared to women with no infection.
There was no association between elevated IL-6 and BV or TV.
Conclusions: These data suggest that both BV and TV detected in
the first half of pregnancy are associated with increased levels of
IL-1 [3. The IL-8 findings may reflect the contribution of PMN’s in
TV infection and possible downregulation of PMN recruitment by
BV pathogens or their metabolic products.
Young Investigator Award
HIGH VAGINAL INTERLEUKIN-8 LEVELS AMONG
WOMEN IN PRETERM LABOR ARE ASSOCIATED WITH
PRETERM DELIVERY. J Hitti, SL Hillier, MA Krohn, DA Es-
chenbach; Department of Obstetrics/Gynecology, University of
Washington.
Objective: To study the associations between vaginal flora, inter-
leukins (IL); and preterm delivery.
Methods: 214 women in preterm labor with intact membranes at
22-34 weeks gestation had vaginal samples collected for Gram
stain, culture, IL-6 and IL-8 determinations by EIA. The distribu-
tions of IL-6 and IL-8 were evaluated using the Mann-Whitney test.
Risk ratios for preterm delivery were calculated for high vaginal
IL-8 in association with normal or disrupted vaginal flora by Gram
stain.
Results: Vaginal IL-8 levels were higher among patients delivering
preterm (p < 0.001):
IL-8 (pg/ml) IL-6 (pg/ml) Delivery at
< 34 Weeks N Median (95% CI) Median (95% CI)
Yes 107 40,960 1,720
(21,380- 77,440) (<700- 3,260)
No 107 10,240 1,660
(5,260 16,630) (<700 2,520)
Vaginal IL-8 levels were significantly higher among patients with
vaginal isolates ofM. hominis (p < 0.01), >106 G. vaginalis or >104
black Prevotella (p < 0.05), but were not significantly higher
among patients with abnormal vaginal flora by Gram stain. High
vaginal IL-8 levels (>75,000 pg/ml) were associated with preterm
delivery independent of vaginal Gram stain characteristics.
Delivery at RR
N < 34 Weeks (95% CI)
Vaginal IL-8 < 75,000 pg/ml
Normal vaginal flora
by Gram stain 94 32 (34%) reference
Bacterial vaginosis/
intermediate flora 66 35 (53%) 1.6 (I. 2.2)
Vaginal IL-8 > 75,000 pg/ml
Normal vaginal flora 30 21 (70%) 2. (I.4 3.0)
Bacterial vaginosis/
intermediate flora 24 19 (79%) 2.3 (I.6- 3.3)
Conclusions: Among women in preterm labor, high vaginal IL-8
may be an independent risk factor for preterm delivery. The rela-
tionships between abnormal vaginal flora and vaginal IL-8 require
further study.
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ESCHERICHIA COLI UTERINE INFECTION IN PREG-
NANT RATS. B Nowicki, MD, PhD 1,2 L Fang, MD J. Singhal,
S Nowicki, DDS 1,2 C Yallampalli, DVM, PhD. Departments of
OB/Gyn, & Microbiology2, University of Texas Medical Branch,
Galveston, TX
Objectives: The mechanism of urogenital infections caused by E.
coli and associated complications during pregnancy is not well
understood. Nitric oxide (NO), an endogenous smooth muscle re-
laxant involved in maintaining uterine quiescence during pregnancy
is considered to participate in an anti-bacterial mechanism. In this
study, we evaluated the effects of mutation of dra operon encoding
E. coli Dr fimbriae and NO inhibitor L-NAME on uterine infection
in pregnant and nonpregnant animals.
Study Design: Rats implanted with osmotic minipumps with either
L-NAME or saline only were inoculated with Dr fimbriae positive
(Dr+) E. coli or its mutant (Dr-) (200 pl 5 x 109 bacterial cells/ml)
into the cavity of the left uterine horn (72 rats on day 18 of preg-
nancy and to 12 nonpregnant). Animals were sacrificed on day
19,20,21 (pregnant) or at and 2 days after infection (nonpregnant).
Rats were monitored for the death rate and preterm labor; kidney,
spleen, liver, uterus, placenta, fetuses, and blood were collected for
quantitative cultures.
Results: Within 24 hours after infection, 31% of pregnant animals
were dead in Dr+ group only. Interestingly, co-treatment with L-
NAME resulted in two-fold increase in death rate (66%) in Dr+
group. No deaths occurred in nonpregnant rats either with or with-
out L-NAME. Infection of the uterus in pregnant animals was 5 x
105/g in the Dr+; 5 x 104/g in Dr- group. In pregnant rats, Dr+ E.
coli in the blood were detectable in 75% of the untreated and 88%
of the L-NAME treated group. The dissemination of infection to the
kidney, spleen, and liver was 8 x 106 bacteria per gram of tissue
with Dr+ E. coli and this was about 3 logs lower (p < 0.01) with
Dr- E. coli. Controls without infection, with or without L-NAME
were unaffected in terms of death or infection spread. No preterm
labor was observed in any pregnant animals.
Conclusions: Dr+ E. coli displayed significantly higher virulence
to pregnant rats only. Inhibition ofNO enhanced the dissemination
of infection and death in the pregnant animals infected with Dr+ but
not Dr- E. coli. We therefore propose that infectious complications
of pregnancy may be related to both 1) gestation-dependent viru-
lence of the pathogen, and 2) the host sensitivity associated with the
NO status.
E. COLI ACQUISITION DURING PREGNANCY AND RISK
OF PRETERM BIRTH. HM McDonald PhD, JA O’Loughlin
FRACOG, R Vigneswaran FRACP, PJ McDonald, FRACP, A
Bof MBBS, MF Annells MHSM, PT Jolley B Pharm,
Kennedy2. 1Women’s & Children’s Hospital, 2Lyell McEwin
Health Service, Adelaide, Australia.
Objectives: Women with preterm birth (PTB) <34 weeks have a
nearly 4-fold higher prevalence of E. coli in labour. The purpose of
this study was to determine the acquisition/carriage of E. coli sero-
groups in the urine and vagina during pregnancy, and relationship
to PTB.
Study Design: Pregnant women with a history of PTB (PPTB) or
of urinary tract infection (UTI), and a control group of women with
no history of PTB or UTI, were enrolled. Cultures of vaginal swabs
(semi-quantitative) and urine (quantitative) were performed at 24,
28, 32, and 36 weeks’ gestation, and in early labour. Women with
age <17 years were excluded.
Results: 474 women were enrolled (151 UTI, 81 PPTB and 242
controls). The demographic characteristics of the three groups were
similar. The spontaneous PTB rates were: 2.1%, 5.4% and 22.1%
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for the control, UTI and PPTB groups. There was little site varia-
tion in the E. coli prevalence/visit in controls (14.9% vagina, 14.7%
urine), although this was greater in PPTB women (18.6%, 14.5%).
Although half the control (49.2%) and PPTB (48.1%) women had
E. coli in the vagina/urine at some stage during pregnancy, 61.6%
of women in the UTI group had E. coli during pregnancy [OR 1.66
(95%CI 1.07-2.56)]. Prevalence increased with advancing gesta-
tion in the UTI and PPTB groups but acquisition during late preg-
nancy or early labour was rare. The most common serogroups were
O 1, 06, 075, 068 and O 16, and two thirds of women with E. coli
had only one serogroup during pregnancy. O1 was significantly
more common in the UTI group than in controls [19.2% vs. 10.3%
OR 2.06 (1.11-3.83)] or PPTB. 06 was the most persistent sero-
group overall. O16 was significantly more common in PPTB
women than in the control [9.9% vs. 2.9%, OR 3.7, (1.1-12.3)] or
UTI [2.0%, OR 5.4 (1.3-32.3)] groups. In the 8 PPTB women with
O16, a 50% PTB rate (<37 weeks) was found vs. 18.8% (13/69) in
the remainder of the PPTB group.
Conclusions: Women with PPTB have an increased vaginal/urine
prevalence of E. coli O16 compared with women with UTI or
controls (despite a higher overall E. coli colonisation in women
with UTI). Women with E. coli O16 and PPTB may have a higher
PTB rate than other PPTB women, but this is not associated with
late acquisition.
HIGH DENSITY GENITAL GROUP B STREPTOCOCCAL
COLONIZATION INCREASES THE RISK OF INTRA-
AMNIOTIC INFECTION. Marijane A. Krohn, Ph.D., Sharon L.
Hillier, Ph.D., Carol J. Baker, M.D.
Objectives: To determine the risk of intra-amniotic infection (IAI)
associated with high density maternal vaginal group B streptococci
(GBS) colonization.
Study Design: A cross-sectional cohort of 5587 women was en-
rolled from 1992 to 1996 in three cities: Houston TX, Seattle WA,
Pittsburgh PA. IAI was defined as fever of 38C accompanied by
two of the following signs: maternal (> 100 bpm) or fetal (> 160
bpm) tachycardia, uterine tenderness, purulent amniotic fluid, and
elevated peripheral WBC count (>15,000). Vaginal specimens ob-
tained at admission for delivery were inoculated into a selective
enrichment broth and blood agar. Agar plates were streaked in four
zones. High density was defined as growth in zones 3-4 and low
density in zones or 2.
Results: The frequency of IAI was: Houston, 2.5% (18/712); Se-
attle, 5.3% (145/2755); Pittsburgh, 0.9% (20/2121). High density
GBS colonization was present in 5% (289/5587), low density in
11% (620/5587), and broth only in 5.4% (302/5587) of women.
After adjusting for city, high density colonization was associated
with an increased risk of IAI (aRelative Risk (RR) 1.85; 95%
Confidence Interval (CI) 1.00-3.25), low density colonization
was associated with a minimally increased risk (aRR 1.18; 95%
CI 0.76-1.80), and broth only was not associated with an in-
creased risk (aRR 0.70; 95% CI 0.33-1.47).
Conclusions: These findings provide further evidence that intra-
partum GBS colonization is associated with maternal complica-
tions. Screening and treatment intervention strategies are necessary
to address IAI, as well as, other previously described complications
of group B streptococcal genital colonization.
THE EFFECT OF INTRAMUSCULAR BENZATHINE PENI-
CILLIN G ON GROUP B STREPTOCOCCUS AND OTHER
VAGINAL FLORA IN PREGNANT WOMEN. Brock BV,
Watts DH, Brown ZA, Agnew KJ, Eschenbach DA. University of
Washington, Seattle, WA.
Objective: To evaluate the efficacy of intramuscular Benzathine
Penicillin G (PCN) on suppression of vaginal Group B Streptococ-
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cus (GBS) colonization in pregnant women and to assess the impact
of therapy on other vaginal flora.
Study Design: Pregnant women with GBS colonization were re-
cruited from High Risk and Diabetes clinics. Vaginal specimens for
gram stain, semi-quantitative culture for GBS, enteric gram nega-
tive rods, Enterococcus and yeast were obtained at baseline and
every one to two weeks after I.M. administration of 2.4 million
units ofPCN and upon admission in labor. All patients who labored
received intrapartum I.V. antibiotic GBS prophylaxis. Cultures
were obtained from between the chorion and amnion at delivery.
Results: 17 patients with GBS colonization received I.M. PCN. 14
patients became GBS culture negative in a median of 7 days (range
4-40) after one injection. Three patients required multiple injec-
tions to become GBS negative. Time to first negative culture was
not related to level of colonization at baseline. Patients remained
GBS negative a median of 32 days after the first PCN injection
(range 14-81) and >21 days after repeat injections (range 14-55+).
One (6%) of the 17 patients was GBS positive at delivery. Changes
in vaginal flora are summarized below:
Baseline Baseline Total
Baseline negative, negative, positive
culture becomes positive at at
positive positive delivery delivery
GNR 4/17 11/13 8/11 10/17
Enterococcus I/I 7 12/I 6 6/12 6/I 7
Yeast 4/17 4/I 3 2/4 2/17
The majority of patients with GNR, Enterococcus and yeast at
delivery are those who acquired these isolates after PCN adminis-
tration. Nine out of 10 women with normal baseline gram stains
remained normal at delivery, while 4 out of 7 with abnormal gram
stains improved. Two (12.5%) of 16 chorioamnion cultures were
positive (1-E. coli, 1-Gardnerella vaginalis). None of the 17 infants
had neonatal infections.
Conclusion: Intramuscular PCN suppressed vaginal GBS coloni-
zation in a majority of patients. This strategy to prevent neonatal
colonization at term needs to be studied in a larger group, however,
the increase in vaginal colonization with GNR and Enterococcus
could increase maternal and neonatal infections from these organ-
isms.
STREPTOCOCCUS AGALACTIAE (GROUP B STREP) RE-
SISTANCE TO CLINDAMYCIN AND ERYTHROMYCIN.
Mark Pearlman, MD, Carl Pierson, PhD., Roger Faix, MD.
Objectives: Current recommendations for Group B strep (GBS)
intrapartum prophylaxis in penicillin allergic patients is the use of
either clindamycin or erythromycin. This study was designed to test
the frequency of resistance of GBS clinical isolates to these and
other frequently used antibiotics.
Study Design: One hundred isolates of Group B Strep collected
from the lower genital tract/anorectum of 100 pregnant women
were utilized for testing. Resistance to clindamycin (100 isolates),
erythromycin (82 isolates), benzyl penicillin (82 isolates), cephalo-
thin (82 isolates) and vancomycin (82 isolates) was tested using
E-test strips on Mueller Hinton agar supplemented with 5% sheep
RBCs incubated in a non-CO2 atmosphere for 18 to 20 hours.
Results:
Most isolates resistant to clindamycin were also resistant to eryth-
romycin; however, three isolates were resistant to erythromycin but
No. (%) resistant to:
Set No. No. tested Clindamycin Erythromycin
8 5 (28) t
2 8 3(7) 5(28)
3 36 4(11) 4(11)
4 28 4(11) 4(11)
Total 100 15 (I 5) 12/82 (I 5)
sensitive to clindamycin and one isolate sensitive to erythromycin
was resistant to clindamycin. All 82 isolates tested were sensitive to
penicillin, cephalothin and vancomycin.
Conclusions: In vitro resistance of GBS to clindamycin and eryth-
romycin occurs in a significant number of clinical isolates. Larger
studies are necessary to confirm these rates of in vitro resistance, to
assess the resultant impact on in vivo efficacy, and to determine if
alternative antibiotics are more appropriate in pencillin allergic pa-
tients. Meanwhile, care providers should be aware of the possibility
of clinical resistance to clindamycin and erythromycin and need to
carefully review the history of penicillin allergy to ascertain if
non-penicillin, non-cephalosporin alternatives are truly indicated.
DETECTION OF BACTERIA IN AMNIOTIC FLUID BY A
MONOCLONAL ANTIBODY TO AN EPITOPE OF THE
ELONGATION FACTOR TU. Penny Clark, Ph.D., Gregory
Locksmith, M.D., J6rg K/3hl, M.D. and Patrick Duff, M.D. Dept.
of Obstetrics and Gynecology, University of Florida and Dept. of
Medical Microbiology, Medical School Hannover, Hannover, Ger-
many.
Introduction: Elongation factor Tu (EF-Tu) catalyzes the binding
of each amniocyl t-RNA to the ribosome. EF-Tu is one of the most
abundant proteins in procaryotes, representing 5% of the total cel-
lular protein of E. coli. MAb 900, a monoclonal antibody against a
highly conserved epitope on the E. coli EF-Tu protein, has been
found to have broad cross-reactivity with more than 90 species of
bacteria.
Objective: To determine if MAb 900 will detect bacteria in amni-
otic fluid. If so, an assay using MAb 900 may be useful in the
diagnosis of bacterial infection of the amniotic cavity.
Study Design: MAb 900, generated by immunization of mice with
E. coli K-12 C600, was used for the assay of EF-Tu by ELISA. The
antibody was tested on several species of aerobes and anaerobes
commonly isolated from the female genital tract. EF-Tu assay was
performed on amniotic fluid (AF) samples that were intentionally
inoculated with known concentrations of pure cultures of E. coli,
Lactobacillus sp., Bacteroides fragilis, Peptostreptococcus, and
group B streptococcus to determine the assay’s limit of detection.
Lysates of E. coli obtained by sonicating whole cells for 2 minutes
in buffer with glass beads were used as standard. A separate set of
40 AF samples were then collected from term (n 20) and preterm
(n 20) pregnancies, cultured for bacteria, and assayed for EF-Tu.
The EF-Tu assay results were compared to culture results.
Results: Amniocytes, RBCs and WBCs in amniotic fluid did not
react to MAb 900, while the species of aerobic and anaerobic
bacteria commonly isolated from the female genital tract showed
strongly positive reactions. The assay by ELISA detected bacterial
concentrations greater than 104 bacteria/mL, and took 8 hours to
perform. Of the 40 test AF samples, 4 had positive cultures. All 36
samples with negative cultures had a negative EF-Tu assay. Of the
4 samples with positive cultures, 2 were detected by the EF-Tu
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 351assay. The 2 samples that were not detected contained less than 102
bacteria/mL.
Conclusion: The monoclonal antibody to a bacterial elongation
factor identifies bacteria in amniotic fluid. At its present level of
sensitivity (104 col./mL), the assay is of greatest value in excluding
bacterial infection of amniotic fluid.
TRICHOMONAS VAGINALIS BUT NOT BACTERIAL VAG-
INOSIS IS ASSOCIATED WITH INCREASED VAGINAL
FLUID DEFENSINS IN PREGNANCY. RP Heine, MD, LF
Mortimer, MS, DL Draper, PhD, HC Wiesenfeld, MD, CM, MA
Krohn, PhD. Magee-Womens Research Institute, Department Ob-
stetrics Gynecology and Reproductive Sciences, University of
Pittsburgh School of Medicine, Pittsburgh, PA.
Objective: T. vaginalis (TV) and bacterial vaginosis (BV) are as-
sociated with adverse pregnancy outcome. The mechanism may
involve an interaction between the pathogen and the host immune
system. We hypothesize that women with an exaggerated immune
response in concordance with specific pathogens have a high risk of
preterm birth. To investigate this hypothesis we initially sought to
determine if neutrophil-specific defensins are elevated in patients
infected with TV or BV.
Study Design: From 7/95 to 1/97, we screened all asymptomatic
pregnant women entering prenatal care at Magee-Womens Hospital
for TV by culture and BV by gram stain at 8-21 weeks gestation.
An additional swab was obtained from the posterior f.ornix and
frozen at-70C for subsequent defensin analysis. Defensin levels
were measured in batch by ELISA. Comparisons between groups
were made by the Mann-Whitney U Test for non-parametric data.
Results: For this study we evaluated 64 women with TV, 60 with
BV, and 62 controls. Patients with TV but not BV had significant
elevations in defensins when compared to controls (p < .005). All
groups exhibited a wide range of defensin levels.
Conclusion: Defensin levels are elevated in pregnant Women in-
fected with TV but not BV. The highly variable levels of elevation
suggest differing degrees of neutrophil activation. Future work will
focus on the degree of defensin elevation and correlation with ad-
verse pregnancy outcome.
300O0
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THE UTILITY OF READILY AVAILABLE CLINICAL
TESTS IN PREDICTING PELVIC INFLAMMATORY DIS-
EASE IN WOMEN PRESENTING WITH PELVIC PAIN.
Soper DE, Peipert J, Ness R, Bass D, Hemsell D, Shepherd S, and
the PEACH Study Group.
Objectives: To determine which tests were sufficiently predictive
as to exclude the diagnosis of PID among women with the mini-
mum clinical criteria (abdominal pain and pelvic organ tenderness).
Study Design: Reproductive age group women with a complaint of
lower abdominal pain and uterine and adnexal tenderness were
prospectively enrolled in a randomized clinical trial comparing in-
patient and outpatient antibiotic therapy for PID (Group 1). After
initiation of the study, additional inclusion criteria [presence of
leukorrhea (vaginal wbc > epithelial cells), mucopurulent cervicitis
and/or positive tests of the cervix for GC or chlamydia] were added
(Group 2). Demographic and clinical variables were assessed in
each group and the incidence of PID (defined as histologic endo-
metritis and/or a positive test for gonorrhea or chlamydia from the
endometrium) was compared. Sensitivity, specificity and positive
and negative predictive values were determined for the following
variables in Group 1; leukorrhea, mucopurulent cervicitis, bacterial
vaginosis, any vaginal wbc, peripheral wbc count (>10,000), and
ESR (>15).
Results: 63 women were enrolled in Group and 174 women were
enrolled in Group 2. There were no significant differences between
Groups and 2 with respect to demographic variables. The inci-
dence of PID was 38.1% (24/63) in Group and 48.9% (85/174) in
Group 2 [p 0.14]. The diagnostic indices for Group were as
follows:
Vagi- Periph-
Leukor- nal eral
rhea MPC BV wbc wbc ESR
Sensitivity 51.2% 68.2% 41.7% 95.5% 55.0% 60.9%
Specificity 70.3% 91.7% 73.0% 21.1% 80.0% 64.1%
PPV 51.2% 83.3% 50.0% 41.2% 61.1% 50.0%
NPV 70.3% 82.5% 65.9% 88.9% 75.7% 73.5%
Conclusions: The evaluation of the lower genital tract for evidence
of inflammation is helpful in the diagnosis of PID. The absence of
vaginal white blood cells during microscopy of the vaginal secre-
tions is the most reliable test that rules out PID.
ACTIONS AND ATTITUDES REGARDING HIV TESTING
IN MINORITY WOMEN WITH STDS. J.M, Piper, M.D., J.H.
Dimmitt, Ph.D., R.N. Shain, Ph.D., E.R. Newton, M.D., S.T. Per-
due, M.D.
Objective: Although universal screening for HIV in pregnancy is
becoming widely accepted, attitudes regarding HIV risk and accep-
tance of HIV testing remain important issues, particularly in the
women at highest risk--low socioeconomic status, minority
women with other STDs. We sought to examine attitudes toward
and acceptance ofHIV testing in a low income, minority population
with active STDs.
Study Design: Black and Hispanic women with an active STD
underwent detailed questioning regarding STD beliefs and risk
behaviors, including those related to HIV. Perception of HIV
risk, HIV knowledge, risk behaviors, and attitudes regarding HIV
testing were assessed, and compared between pregnant and non-
pregnant women. HIV testing was offered to all women after the
interview.
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Pregnant vs.
Attitude/Action Overall Non-pregnant P
Denied HIV Risk 52% 60% vs 49% <0.02
Did Not Know How
HIV Is Spread 6% 9% vs 4% <0.05
No Prior HIV Test 46% 55% vs 42% <0.005
Tested, But Never
Got Results 26% 26% vs 26% NS
Continued to Refuse
Testing 9% 9% vs 9% NS
None of the women were found to be HIV positive.
Results: 195 Black and 425 Hispanic women with an active STD
were interviewed, of whom 184 (30%) were pregnant. Current
STDs included gonorrhea (21%), chlamydia (69%), and tricho-
monas (23%).
Conclusions: Low perception of HIV risk is a significant impedi-
ment to voluntary HIV testing, even in women at high risk. Strat-
egies to encourage HIV testing and reduce HIV transmission must
focus on both reducing risk behavior and improving perception of
HIV risk, particularly in high-risk populations.
EFFECTS OF CHLORHEXIDINE GEL AND NON-
OXYNOL-9 ON VAGINAL FLORA AND EPITHELIUM.
DH Watts, L Rabe, MA Krohn, Aura, SL Hillier. University of
Washington, Seattle, WA and University of Pittsburgh/Magee-
Womens Research Institute, Pittsburgh, PA.
Objective: To evaluate the effects of a single dose of chlorhexidine
gluconate (CHG) gel or nonoxynol-9 (N-9) gel on vaginal flora and
epithelium.
Study Design: Women underwent history, physical and colpo-
scopic examination, vaginal Gram stain, and quantitative vaginal
cultures at baseline and 30’, 4, and 1, 2, 3, and 7 days after
instillation of 2 ml of 0.05% CHG gel (Surgilube(R)) (n 17) or one
applicatorful of 4% N-9 gel (Conceptrol(R)) (n 8).
Results: No changes in the vaginal epithelium were noted by col-
poscopy after CHG or N-9. After CHG, concentrations of H202+
and H20-
lactobacilli (LB), and Enterococcus decreased by 0.8-
1.1 log at 30’ and 4, but returned to baseline by 24. The one
subject with group B Streptococcus at baseline became GBS nega-
tive thru day 2, but was positive again on day 3. Vaginal Gram stain
results did not change significantly after CHG. After Conceptrol
instillation, concentrations of H202+ LB decreased by 1-2 log at
30’ and 4 but returned to baseline by 24 while H20-
LB levels
did not change. Concentrations of Enterococcus, anaerobic Gram
negative rods, and G. vaginalis decreased also at 30’ and 4. Vagi-
nal Gram stain scores increased on days 2 and 3, then returned to
baseline. Three women acquired E. coli after N-9 instillation, and
the subject with E. coli at baseline had a 3-4 log increase in level
at 4 and 24.
Conclusions: Single doses of intravaginal CHG and N-9 were well
tolerated. Both CHG and N-9 caused transient decreases in most
vaginal bacteria, but N-9 use may increase E. coli colonization.
Further evaluation of activity of these agents against sexually trans-
mitted pathogens is required. Supported by NIH grant # AI 37830.
DETECTION OF HUMAN IMMUNoDEFICIENCY VIRUS
(HIV) AND HUMAN PAPILLOMA VIRUS (HPV) IN NOR-
MAL AND DYSPLASTIC CERVICAL TISSUE BIOPSIES
BY IN SITU POLYMERASE CHAIN REACTION (IS-PCR).
Antonio Sison, Ashit Sarkar, Ashraf Hassanein, Joan Smith, Mi-
chael Spence, Lisa Bobroski, Farida Shaheen, Deirdre Gundy,
Omar Bagasra
Objectives: The role of HIV and HPV in cervical dysplasia among
HIV-infected women is poorly understood. Normal and dysplastic
cervical biopsies from HIV-infected nonpregnant women were
studied 1) to assess the frequency of detection and 2) to determine
the location of HIV and HPV using the technique of IS-PCR.
Study Design: 37 cervical biopsies from 29 HIV-infected patients
were tested for HIV and HPV using IS-PCR. Tissues were sub-
jected to DNA amplification using conserved regions of HIV gag
gene, HPV, and HLA-DQo for control. Detection was achieved
with biotinylated probes.
Results: Median CD4 count was 282 cells/mm3. The table shows
IS-PCR results for HIV and HPV in relation to the histology:
# Positive # Positive
Histology # HIV (%) HPV (%)
Normal 19 6 (32) 4 (21%)
Mild-to-moderate dysplasia 7 2 (29) 2 (29)
Severe dysplasia 8 3 (37) 4 (50)
HPV only 3 1(33) 0 (0)
HPV and dysplasia 6 2 (33) (17)
Dysplasia in the cervix did not correlate with the likelihood of
detecting HIV (trend X-square, p > 0.20), but a trend was noted for
HPV to be detected more often as the dysplasia worsened (p
0.045). No correlation was found between detection of HIV/HPV
and absolute CD4 (p > 0.20). For both HIV and HPV, positive
signals were seen in macrophages and epithelial cells, especially
showing squamous metaplasia and the superficial layers of the
stratified epithelium. Overall, dysplastic cells and koilocytes on
histology were not consistently positive to HIV and HPV by IS-
PCR.
Conclusions: 1) HIV and HPV are detectable within cervical tissue
by IS-PCR from HIV-infected women in one third of cases, mostly
in macrophages but in epithelial cells as well, 2) there was no
correlation between detection of HIV by IS-PCR to severity of
dysplasia, although there was a trend for increased detection of
HPV with dysplasia. These findings suggest that HIV in the cervix,
unlike HPV, may actually play little or no direct pathogenic role in
cervical dysplasia. (Slides will be presented.)
CULTURE VERSUS POLYMERASE CHAIN REACTION
(PCR) FOR DETECTION OF CHLAMYDIA TRACHOMATIS
IN AN INTERMEDIATE PREVALENCE POPULATION.
KA Boggess MD, CH Livengood III MD, AP Murtha MD, and
Wrenn BS. Duke University Medical Center, Durham, NC.
Objective: To compare the accuracy of culture and PCR for de-
tection of Chlamydia trachomatis (CT) in an intermediate preva-
lence population.
Study Design: Paired endocervical specimens first for CT culture
and then for PCR were collected from 1583 unselected women at
risk for CT from 12/5/95-8/31/96. Culture was performed with one
blind passage, and PCR was performed in duplicate. Discrepant
pairs were re-tested by PCR with the plasmid DNA primer and, in
the first 600 specimens, with 2 additional target primers. To com-
pare PCR to culture, discrepancy resolution was performed. All true
+ specimens were defined as any culture+, or PCR+ by >2 assays
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data from patients with discrepant results were reviewed.
Results: 95/1583 (6%) were both culture and PCR+. The preva-
lence ofCT detected by culture was 7.3%, versus 8.1% by PCR. All
PCR samples were plasmid-. There was a significant association
between culture and PCR results, (P < .001, Fisher’s exact test).
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ofBZK alone or in any combination. Lactobacilli were decreased in
the BZK only treatment group. All microflora levels recovered
within one week of no microbicide use.
Conclusions: Although N9 is currently the only microbicide ap-
proved for use as a spermicide in this country, its repeated use may
be detrimental to the epithelial tissues of the female reproductive
Initial results
+ Cult-
Results following discrepancy resolution
PCR+ PCR- Cult+ Cult-
PCR+ 95 (6%) 33 (2%) True+
PCR- 20 (1%) 1435 (91%) True-
128 (86%)
0
20 (I 4%) II S (78%) 33 (22%)
1435 (100%) 0 1435 (1005%)
Following discrepancy resolution, the sensitivity of culture was
78%, and of PCR, 86%. The PPV and NPV of culture were 100%
and 98% respectively, and the PPV and NPV of PCR were 100%
and 99% respectively. Of the 20 cult+/PCR- pairs, 12 cultures were
positive only on subculture. The cost/specimen for culture was
$18.84 and for PCR $18.88.
Conclusions: A high quality culture technique remains competitive
with PCR for the detection of CT in an intermediate prevalence
population. The use of PCR when low amounts of chlamydia are
present remains to be determined. Direct costs for PCR and culture
are equivalent.
EFFECTS OF MULTIPLE APPLICATIONS OF NON-
OXYNOL-9 AND BENZALKONIUM CHLORIDE ON VAGI-
NAL TISSUES AND MICROFLORA IN A MONKEY
MODEL. DL Patton PhD, GM Ganzle Kidder, YT Cosgrove
Sweeney, LK Rabe, SL Hillier PhD. Depts. of Obstetrics & Gyne-
cology, Univ. of Washington, Seattle WA, and Magee-Womens
Hospital, Univ. of Pittsburgh, Pittsburgh, PA, USA
Objectives: To evaluate nonoxynol-9 (N9) and benzalkonium chlo-
ride (BZK) as topical microbicides which may help control the
spread of STDs. In the macaque model, we assess the effects that
multiple applications of these candidate agents have on vaginal
flora and lower reproductive tract tissues.
Study Design: Monkeys received repeated intravaginal applica-
tions of N9 (n 4), BZK (n 5), or N9 + BZK (n 5). Each
animal received the microbicide(s) daily for 3 to 5 days. Gross
colposcopic observations and vaginal microflora assessments were
performed on all animals prior to, throughout and following
completion of microbicide applications. Cervical biopsies for his-
topathological analysis were also collected from all animals.
Results: At colposcopy, cervical and vaginal erythema was ob-
served in all microbicide groups. Papillae and epithelial disruption
were apparent on the cervical tissues in all groups treated with N9.
Epithelial disruption of the vaginal tissues was additionally noted in
the BZK only and N9 + BZK group. Histopathology of the cervical
biopsies detected acute inflammatory infiltrate and an influx of
plasma cells in all treatment groups, and lymphoid follicles, indica-
tive of chronic inflammation in some specimens. Microflora as-
sessments revealed transient decreases in anaerobic gram negative
rods and peptostreptococci in all microbicide groups. N9 induced a
transient increase in Staph aureus levels, when applied alone or in
combination with BZK. Viridans levels decreased after application
tract. BZK, which is approved for use in other countries may not
only damage epithelial tissues, but also appears to reduce the popu-
lation of potentially protective lactobacilli in the vagina.
Supported in part by grants P01-AI-39061 and CONRAD sub-
project CSA-95-161.
EYE SPLASH IN GYNECOLOGICAL PROCEDURES.
Donnell Bradford, M.D., Andrew Helfgott, M.D., Ronald Lorimor,
Ph.D.
Objectives: To determine the rate of face splash during gyneco-
logical procedures, and to identify the personnel and procedures
with the highest risks.
Study Design: Opti-Shield face shields were worn during operative
gynecological procedures. The masks were then collected from
participants. Shields were visually examined for evidence of con-
tamination. The face shields were subsequently immersed in hy-
drogen peroxide (H202) to confirm contamination by splash. The
Gauss statistical program was used to perform Pearson’s Chi-
square test.
Results:
Visual splash 157/521 (30%)
H202 positive 169/521 (32%)
Procedures with splashes:
Personnel with splashes:
Postgraduate year
Major
abdominal 73/154 (47%) PGY 17/57 (30%)
Minor
abdominal 20/93 (22%) II 42/I 56 (27%)
Vaginal 56/I 21 (46%) III 44/I 12 (39%)
Laparoscopic 1/76 (I 5%) IV 50/140 (36%)
Minor 9/77 (12%) Attending 12/33 (36%)
P < 0.0001 Student 4/23 (I 7%)
P < 0.0001
Results: Thirty two % of personnel performing gynecological pro-
cedures had face splashes as determined by H202 immersion. This
32% splash as determined by H20 had a 95% C.I. of _+4.0. PGY
III, PGY IV, and attendings were exposed at the highest rate. Risk
of exposure was greatest during major abdominal and vaginal sur-
gery.
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Conclusion: Certain gynecology procedures place surgical partici-
pants at significant risk for exposure to eye splash. This data sup-
ports the use of Opti-shield face protectors in operative gyneco-
logical procedures.
COMPLIANCE WITH UNIVERSAL PRECAUTIONS:
KNOWLEDGE AND BEHAVIOR OF RESIDENTS AND
STUDENTS IN A DEPARTMENT OF OBSTETRICS AND
GYNECOLOGY. Francisco J. Garcini M.D., Ph.D., Jennifer Tay-
lor-Burton, M.P.H., Richard Grimes, Ph.D., Andrew Helfgott,
M.D., Nancy Eriksen, M.D., Jorge D. Blanco, M.D.
Objectives: To assess the knowledge of universal precautions (UP)
for the delivery and operating rooms by residents and students, and
to evaluate their use of UP.
Study Design: Obstetrics and Gynecology (OB/GYN) residents (n
24) and students (n 18) from an inner-city, teaching hospital
were polled by anonymous questionnaire to assess their knowledge
of the appropriate barrier equipment for certain OB/GYN proce-
dures. To determine actual compliance with UP, 459 OB/GYN
procedures were observed. We noted the use of appropriate barrier
equipment for each procedure: pelvic exam (gloves), vaginal de-
livery, cesarean, D&C (face shields, gowns, gloves, booties). The
True Epistat statistical program was used to perform linear regres-
sion analysis.
Results: Twenty four (100%) residents knew the appropriate barrier
equipment required for each type of procedure performed. One (5%)
student did not know that booties were appropriate for the surgical
procedures. Rationale for lack of compliance with UP elicited by the
questionnaire included: time constraints (60%), inconvenience (50%),
and presumption that patient was not infected (33%).
The observed rate of compliance with UP by participants was:
vative approach now advocates drainage via laparotomy, laparos-
copy or transabdominal invasive radiology. Transvaginal drainage
via culdotomy is usually reserved for PA "pointing" into the cul-
desac. Given recent advances in TVS with biopsy guidance sys-
tems, we report our experience with this minimally invasive tech-
nique.
Study Design: A retrospective analysis, from 1991-1995, was car-
ried out on 27 consecutive cases of PA (13 tuboovarian (TOA)
associated with pelvic inflammatory disease; 14 postoperative
(POSTOP)) undergoing TVS drainage. Demographic, clinical,
laboratory and outcome data were extracted by chart review and
examination of ultrasound files. Failure of the procedure was de-
fined as persistence of symptoms and need for additional operative
interventions.
Results: The mean patient age for the study group was 39 years.
Mean duration from diagnosis to drainage was 5.6 days (TOA) and
2.0 days (POSTOP); p < 0.01. All patients received broad spectrum
intravenous antibiotics from admission to resolution of acute symp-
toms. The mean diameter of the PA was 86 mm; from 70-750 cc of
purulent material was drained with each procedure. Perceived ad-
equacy of drainage was correlated to lack of septations within the
PA. Culture results were positive in 51% of cases (79% POSTOP,
23% TOA; p < 0.05) with 1.9 organisms/positive culture. TVS
drainage was successful in 25 of 27 cases (93%). Failures occurred
in one TOA and one POSTOP case. There were no complications
reported.
Conclusion: TVS guided aspiration of PA is a highly successful
technique with minimal risk associated with the procedure. Given
that "pointing" is not a prerequisite, this procedure might be con-
sidered earlier in the course of the disease process, when fewer
septations and more adequate drainage can be anticipated. Although
we speculate that this adjunctive procedure should result in an
improvement of long-term outcome, follow up studies are needed to
Number of
observed Gloves
Personnel procedures %
Gown Face Shield Booties Overall
% % % %
Students 100 100 99 91 95 96
Residents 359 100 94 71 87 88
Individual compliance was inversely related to the years of experience
(overall compliance rate of students was 96% (1 st year residents 92%,
2nd year 89%, 3rd year 84%, and 4th year residents 78%), (r
-0.9918, p 0.0009).
Conclusions: Knowledge regarding UP was nearly 100%, while
overall observed compliance was only 89%. Compliance with UP
was better among students (96%) than among residents (88%).
Compliance with UP was inversely related to years of experience.
TRANSVAGINAL SONOGRAPHY (TVS) GUIDED ASPIRA-
TION OF PELVIC ABSCESSES (PA). P. Corsi, M.D., S.
Johnson, M.D., M.P. Diamond, M.D., S.G. McNeeley, M.D., B.
Gonik, M.D. Depts. Ob/Gyn and Radiology, Wayne State Univer-
sity, Detroit, MI.
Objective: PA unresponsive to antimicrobial therapy traditionally
required operative extirpation of involved tissues. A more conser-
assess the occurrence of involuntary infertility, ectopic pregnancy
and chronic pelvic pain.
THE ROLE OF MATERNAL GENITAL HSV TITER AND
STAGE OF DISEASE IN NEONATAL HSV TRANSMIS-
SION. ZA Brown 1, S Selke3, J Zeh3, R Ashley2, DH Watts 1, L
Corey2. Departments of Obstetrics and Gynecology, Labora-
tory Medicine and Biostatistics3. University of Washington,
Seattle, WA.
Objectives: It is uncertain what factors are involved in perinatal
HSV transmission. Factors proposed include site of shedding, stage
of disease, viral load, duration of fetal exposure, status of mem-
branes, fetal scalp electrodes and type specific HSV antibody in the
fetal circulation. To address this problem, we performed quantita-
tive PCR on the genital secretions of women at the time of labor.
Study Design: Between 1989 and 1995, 17,197 women had swabs
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for genital HSV studies obtained at the time of labor; 108 were
culture positive, 17,089 were negative. Quantitative PCR was per-
formed on 73 of the 108 and 2 of the 17,089 women. Of the 75
women with quantitative PCR, lesions were present in 24, HSV
serology was available on 73 (6 first episode and 67 reactivation)
and vaginal delivery occurred in 45 (4 with neonatal transmission
Results: There was no relationship between the titer of HSV DNA
in genital secretions and whether neonatal HSV transmission didor
did not occur (Figure 1), whether the presence of i:tSV!in genital
secretions was secondary to first episode or recurrent disease (Fig-
ure 2), or whether lesions were present or absent (Figure 3).
Conclusions: The quantity of HSV DNA in genital secretions does
not appear to be related to the clinical stage of maternal disease, the
presence or absence of clinical lesions and does not appear to be a
major determinant for HSV neonatal transmission.
INFLUENCE OF THE NORMAL MENSTRUAL CYCLE
AND COMBINATION ORAL CONTRACEPTIVES ON
VAGINAL EPITHELIUM AND FLORA. DL Patton PhD, SS
Thwin MS, KJ Agnew BS, DA Eschenbach MD. University of
Washington, Seattle, WA.
Introduction: The effect of hormone levels on vaginal epithelial
thickness may influence the transmission of STDs.
Objective: Examine vaginal tissue and flora during three phases of
the menstrual cycle, and before initiation and after two months of
combination oral contraceptive (OC) use.
Study Design: We examined vaginal tissue in two groups of
women. Vaginal biopsies and cultures were obtained during three
phases (dl-5, d7-12, d19-24) of the normal menstrual cycle (n
52) or before initiation and after two months of combination OC
(35 Ixg of ethinyl estradiol and mg of norethindrone) use (n
27). Histologic and microbiologic assessments were made by ob-
servers blinded to clinical data.
Results: In the normal menstrual cycle group, the mean number of
epithelial cell layers underwent a small but significant decrease
from 29.7 _+ 0.8 on days 1-5 to 28.9 ___
0.7 on days 7-12 and 26.9
_+ 0.7 on days 19-24 of the menstrual cycle (p 0.03). Non-
ovulating women had a reduced mean epithelial cell layer count on
days 7-:t2 (23.7 _+ 1.3) compared to ovulating women (29.8 _+ .9, p
0.003).
The mean number of epithelial cell layers on days 19-24 prior to
(29.6 _+ 1.1) and after two months of combination OC use (29.7 _+
1.1) was similar (p 0.9). The number of polymorphonuclear
leukocytes, inflammatory foci, lymphoid follicles, plasma cells and
macrophages was minimal and similar in all groups studied.
Among women with any vaginal Lactobacillus, the proportion with
moderate to heavy growth of other vaginal bacterial species (>105
bacteria/ml) decreased from 61% (25/41) at 1-5 days to 31% (15/
49) at 7-12 days and 46% (23/50) at 19-24 days of the cycle (p
0.02). No such change occurred in women with no vaginal Lacto-
bacillus or after OC use:
Conclusion: Small but significant differences in vaginal epithelial
thickness and flora were seen during the menstrual cycle. Oral
contraceptive use did not appear to influence vaginal epithelial
thickness or flora.
Supported by R01 HD 33203, NICHD, Contraceptive Development
Branch.
A COMMENSAL RELATIONSHIP BETWEEN PRE-
VOTELLA BIVIA AND PEPTOSTREPTOCOCCUS ANAERO-
BIUS INVOLVES AMINO ACIDS: POTENTIAL SIGNIFI-
CANCE FOR BACTERIAL VAGINOSIS. Vivien Pvbus, PhD
and Andrew B. Onderdonk, PhD.
Objectives: Bacterial vaginosis (BV) has a complex microbiology
which includes anaerobes such as Prevotella bivia and Peptostrep-
tococcus anaerobius, and the facultative organisms Gardnerella
vaginalis. An understanding of interactions between BV-associated
organisms can contribute to the knowledge on both the pathogen-
esis and maintenance of this syndrome. The objective of the current
study was to describe any symbiosis between P. bivia and P. an-
aerobius.
Study Design & Results: We observed that P. anaerobius was
unable to grow in pure culture in vaginal defined medium (VDM),
anaerobically in both batch and continuous culture. However, under
the same conditions, when P. bivia was simultaneously present, P.
anaerobius growth was supported. In quadruplicate experiments
the maximum detectable concentration of P. anaerobius increased
from a mean of loglo 8.57 cfu/mL in peptone-supplemented VDM
to logo 8.94 cfu/mL (P 0.014) when grown in the same medium
conditioned by prior growth of P. bivia. Collectively, these results
suggest that P. bivia stimulates the growth of P. anaerobius, and
that a commensal symbiosis may exist between these organisms.
To chemically define this relationship, culture supernatants from
P. bivia growth were analyzed for amino acid content relative to
control (uninoculated) media. The following amino acids produced
by P. bivia (in the decreasing concentration range indicated) were
subsequently shown to be utilized by P. anaerobius during growth
in P. bivia-conditioned supernatants: alanine (1.5 mM), glycine,
leucine, glutamate, phenylalanine, tyrosine, valine, aspartate, me-
thionine, lysine and proline (0.15 mM).
Conclusions: Amino acid flow from P. bivia to P. anaerobius is
proposed as a mechanism to support a commensal relationship be-
tween these organisms. We have previously found P. bivia growth
stimulatory for G. vaginalis, and the concentration of Prevotella
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spp. to be an important predictor of the health of the vagina.
Potentially, these results underscore the significance of elevated,
vaginal carriage of Prevotella spp.
References:
Pybus, V. and A.B. Onderdonk (1997). Journal of Infectious
Diseases 175:406-415.
2 Lee, M.-L.T., Ross, R.A., Delaney, M.L. and A.B. Onderdonk
(1994). Microbial Ecology in Health and Disease 7:235-240.
Best Abstract Award
HEPATITIS C VIRUS INFECTION IN PREGNANCY: IS
MATERNAL VIRAL BURDEN RELATED TO VERTICAL
TRANSMISSION? NS Silverman, MD, FN Jaffee, MD, RL
Hodinka, PhD. Department of Obstetrics and Gynecology, Division
of Maternal-Fetal Medicine, Thomas Jefferson Medical College of
Thomas Jefferson University Hospital, and Departments of Pediat-
rics and Pathology, Children’s Hospital of Philadelphia, Philadel-
phia, PA.
Objective: We performed quantitative evaluation of serum titers of
hepatitis C virus (HCV) in a cohort of substance-addicted, HCV-
RNA-positive pregnant women to test the hypothesis that the level
of maternal viremia near term was related to the risk of vertical
HCV transmission.
Study Design: All 23 HCV-antibody-positive women identified
prospectively through routine screening over a 15-month period
gave consent for additional blood to be drawn from them, at 32-36
weeks, and from their newborns. These study samples were ana-
lyzed for the presence of HCV-RNA-specific sequences via quali-
tative PCR, with positive samples then quantitatively tested via a
branched DNA (bDNA) assay with a lower level of sensitivity of
0.2 HCV-RNA MEq/ml.
Results: Of the 23 anti-HCV-positive women in this study, 18
(78%) were HCV-RNA-positive, with paired maternal-neonatal
samples available for 17 of these 18 pregnancies (one’term fetal
demise). Three antibody positive women were also HIV-infected,
with 2 among the 18 (11.1%) in the HCV-RNA-positive group. One
of the 17 infants (5.9%) born to RNA-positive mothers had HCV-
RNA detected in its serum; this mother was also HIV-infected.
Women who were RNA-positive had a higher mean SGOT than
those who were antibody-positive but RNA-negative (28.2 _
13.2
vs 12.8 _
2.3, p 0.02); their median bDNA titer was 2.76 MEq/
ml (range 0.2-61.8). Median bDNA titers for women with normal
and abnormal SGOT (cutoff 30 IU/1) were not significantly differ-
ent (1.2 vs 3.4 MEq/ml; p 0.88 by Mann-Whitney). The 2
RNA-positive HIV-infected women had low bDNA titers (0.46 and
0.28 MEq/ml), with the HCV-transmitting mother’s value the lower
of the two.
Conclusions: The risk of vertical HCV transmission in this high-
risk cohort was 6%, and was related more to maternal HIV status
than HCV viral titer by quantitative assay. There was no relation
seen between maternal HCV titer and liver function test abnormali-
ties.
AN OFFICE-BASED INTERVENTION TO IMPROVE VAC-
CINATION OF PATIENTS AT RISK FOR SEXUAL
TRANSMISSION OF HEPATITIS B VIRUS INFECTION.
Harold S. Margolis, MD, H. Hunter Handsfield, MD, R. Jake Ja-
cobs, MPA, Joseph E. Gangi, BS.
Objectives: Assess the frequency with which patients at risk of
sexually transmitted hepatitis B virus (HBV) receive counseling
and vaccination from private practice physicians, and assess the
impact of raising physician awareness and offering intervention
tools.
Study Design: Materials were provided to assist in both retrospec-
tive identification of patients at risk of sexually acquired HBV
infection, and counseling concerning HBV infection prevention.
The program’s effectiveness was assessed in a study conducted in
practices across the United States. Physicians were randomized to
either an intervention or current practices group. The intervention
group used letters, educational materials and follow-up telephone
calls to encourage patients to make an appointment to discuss HBV
prevention and vaccination. Physicians in the current practices
group received no identification, contact or counseling materials.
Results: Forty-nine practitioners (13 family physicians, 36 OB/
GYNs) provided baseline data on 457 patients at risk of sexually
transmitted HBV. Twenty-eight physicians provided follow-up in-
formation for 226 patients. At baseline, only 6.5% of patients were
counseled regarding risks of HBV infection, 2.4% started a vacci-
nation series, and 0.7% had completed vaccination. Counseling was
least likely to occur in OB/GYN practices, among uninsured pa-
tients, and among patients without a risk factor other than a recent
sexually transmitted disease. Following the six-month study period,
44% in the intervention versus 15% in the current practices group
received HBV counseling (p < 0.01). Patients in the intervention
group were also more likely to begin (12.6% versus 0.9%, p < 0.01)
and complete (4.8% versus 0.0%, p 0.03) a vaccination series.
Conclusions: Prospective use of this intervention for identification,
counseling, and vaccination of high-risk women should be evalu-
ated.
EVALUATION OF U.S. PERINATAL HEPATITIS B VIRUS
PREVENTION ACTIVITIES. Frank J. Mahoney, MD, and
Nicole M. Smith, MPH, MPP, Hepatitis Branch, CDC
Objectives: To estimate progress toward the national disease re-
duction goal and objectives for preventing perinatal transmission of
the hepatitis B virus.
Study Design: Surveys of hepatitis coordinators from federally-
funded projects were conducted in 1994-1996. Medical record re-
views and hospital policy surveys in five states provided additional
information about maternal hepatitis B surface antigen (HBsAg)
screening rates and vaccination practices for infants born to
HBsAg+ mothers.
Results: Coordinators reported that estimated maternal screening
rates vary from <50% to >90%. However, rates in the five states
ranged from 88% to 96%. Several risk factors for lack of maternal
HBsAg screening were identified, including absence of hospital
policies for maternal HBsAg testing, absence of prenatal care and
public assistance payment for delivery. During the 1993 to 1995
time period, 7691-8258 annual births to HBsAg+ women were
identified, compared to the 20,000 births estimated to occur. States
identifying >90% of the expected number of births to infected
mothers include those that have computerized tracking systems,
hospital reporting systems, and universal reporting of maternal
HBsAg status on newborn screening cards/birth certificates. Of the
identified infants, 88-93% received hepatitis B vaccine and HBIG
at birth, and 61-71% completed the vaccine series by 6-8 months
of age. Between 15-22% of identified infants had post-vaccination
serologic testing and each year only 3% were HBsAg-positive.
Conclusions: Activities to prevent perinatal HBV transmission
have been well-integrated into routine prenatal care. However, uni-
versal HBsAg screening of pregnant women has not been achieved
and comprehensive case management of infants born to HBsAg-
positive women has not occurred. Improved efforts are necessary if
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year 2000.
THE ERADICATION OF HUMAN PAPILLOMA VIRUS
IN WOMEN WITH CONDYLOMA ACUMINATA.
Stanley A. Gall, M.D.; Zhemin Lei, Ph.D.; C.V. Rao, Ph.D.
Objectives: To determine whether a prolonged course of alpha
interferon could eliminate human papilloma virus.
Study Design: A pilot study of ten women were treated with lym-
phoid interferon via systemic subcutaneous infection with a dose of
2.5 million units three times weekly, self administered for six
months. Vulvar biopsy of the wart and subsequently the wart area
were done at the initiation of the study and for six consecutive
months. Photographs were taken of the vulva on each visit. The
biopsies were examinated by autoradiography and by polymerase
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chain reaction. (PCR) The patients clinical course was followed.
Follow up time has been greater than five years.
Results: All ten patients in the pilot study cleared their condyloma
acuminata during the course of therapy. In the follow up five year
period, five patients had recurrence of their condyloma acuminata
but five patients have not had recurrence. The autoradiography
results showed a progressive diminution in the presence of HPV
with each subsequent biopsy in the five patients whose condyloma
did not recur while continuing positive results were seen in patients
whose condyloma subsequently recurred. The PCR results showed
the absence of HPV on the final biopsies of those women who
condyloma has not recurred in five years of follow up.
Conclusions: The therapy of condyloma acuminata with six
months of interferon in a protocol similar to the Hepatitis C pro-
tocols, caused the elimination of HPV in five of ten women. The
same five women who became PCR negative have not experienced
a recurrence of condyloma acuminata after a five year follow up.
POSTER SESSIONS
WOMEN’S BELIEFS ABOUT STD. Edward R. Newton M.D.,
Mark Funk, M.D., Rochelle Shain, Ph.D., Jeanna Piper, M.D., San-
dra Perdue, DPH
Objective: We sought to measure women’s knowledge about STD.
Study Design: In a six week period, 628 of 638 (98%) unselected,
consecutive women attending general gynecology clinics at the
Robert B. Green Outpatient Center filled out a short questionnaire
which surveyed their demographics, STD history, and their STD
knowledge (17 multichoice questions). These questions measured
the woman’s assessment of partner risk, symptoms of STD, con-
sequences of STD, STD acquisition, and response to treatment.
Results: The characteristics of the population were: Black (34%),
Hispanic (52%), Anglo (8%), other race (6%), <21 y/o (31%), <12th
grade education (49%), IV drug use (2.8%), H/O STD (24%),
H/O > STD (32%), nulligravida (34%). The women gave wrong
answers in 34% (_+16%) of questions. The common errors (%
wrong) concerned: symptoms in women (77%), natural history of
untreated STD (98%), acquisition from oral sex (32%), and infer-
tility from STD (53%), the use of drugs or alcohol with problems
using condoms (74%). Twenty percent of women did not consider
AIDS a STD.
Conclusions: Minority women of lower socioeconomic status have
fair knowledge concerning STD. Educational efforts might focus on
symptoms (or lack of) in women, long term consequences, barriers
to condom use, and mechanisms of acquisition.
THE INCREASED INCIDENCE OF GYNECOLOGIC DIS-
EASES IN HIV INFECTED WOMEN: THE ROLE OF HIV
INFECTION VERSUS OTHER RISK FACTORS. Riley L*,
Jarek C, Steger K, Craven D. Mass General Hospital* and Boston
Medical Center, Boston, MA.
Objectives:
1. To compare rates of specific gynecologic abnormalities among
a group of HIV-infected women (cases) versus HIV-negative
high risk women (controls).
2. To assess these rates by other risk factors, such as injection drug
use (IDU) and numbers of lifetime sexual partners.
Study Design: We prospectively performed gynecologic examina-
tions, collected routine cultures and relevant medical data on 232
cases and 20 controls from November, 1992-December, 1996.
Results: Cases and controls were similar in terms of age (35.2 yrs.
vs 35.1 yrs. respectively). Cases were 32% white, 39% black, 13%
Latino, 11% Haitian; controls were 55% white, 35% black, and
10% Latina. IDU was reported by 53% of cases and 70% of con-
trois. Twenty-eight percent of cases and 25% of controls reported
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having >21 lifetime sexual partners (NS). Gynecologic abnormali-
ties either reported in the patient’s history or diagnosed on exam:
H IV-infected H IV-negative
GYN disease n 232 n 20
Gonorrhea 86 (37%) 8 (40%)
Chlamydia 50 (22%) 5 (50%)
PID 47 (20%) 6 (30%)
HPV 42 (I 8%) 5 (25%)
HSV 44 (I 9%) (5%)
Dysplasia* 73 (3 I%) 0
Amenorrhea 70 (30%) 6 (30%)
*Dysplasia was the only abnormality which was significantly different
between the groups (p 0.0013). Of those women reporting any STD,
cases had a 3.5 fold increase in recurrent Chlamydia and a 2.4 fold
increase in recurrent gonorrhea over controls.
Conclusions: Sexually transmitted diseases (STD) were common
in our population of HIV-infected women and high risk HIV sero-
negative controls. The cases reported more recurrences of GC and
Chlamydia than controls. The rate of dysplasia was significantly
increased in HIV-infected women. Amenorrhea was predominantly
associated with active dry users in both groups. The high rate of
gynecologic abnormalities among HIV-infected women may be
due, in part, to other lifestyle risk factors.
TOUGH TO TREAT TRICHOMONIASIS: RESULTS WITH
PAROMOMYCIN CREAM. P Nyirjesy, MD; JD Sobel, MD;
MV Weitz, MSN; DJ Leaman, BSN; SP Gelone PharmD. Temple
University School of Medicine, Philadelphia, PA and Wayne State
University School of Medicine, Detroit, MI.
Objective: To assess the efficacy of 6.25% paromomycin cream in
the treatment of women referred with vaginal trichomonal infec-
tions where metronidazole resistance or allergy was present.
Study Design: The records of 6 patients who were treated with
paromomycin cream were reviewed. Trichomoniasis was diag-
nosed by wet mount with culture confirmation as needed. Patients
used a 4g applicator of cream (250 mg of paromomycin) nightly
intravaginally for 14 days. Results immediately and month after
treatment were reviewed.
Results: The median age was 43 (range 29-49). Three patients
were nulliparous. The median symptom duration was 7.5 years
(range 0.5-14). Three women were allergic to metronidazole. Three
had infections which were resistant to high dose metronidazole. All
6 patients had negative saline preparations after treatment, but 2 had
positive cultures. A third patient’s infection relapsed two weeks
after treatment. Of these failures, one was later cured with a 3-week
course of paromomycin cream. Two patients, both at the same
clinical center, developed vaginal ulcerations during treatment
which resolved spontaneously.
Conclusions: Paromomycin cream cured 2/3 of trichomonal infec-
tions where metronidazole resistance or allergy was encountered.
Adverse effects may have been a result of the local formulation.
4% CROMOLYN CREAM FOR VULVAR VESTIBULITIS:
RESULTS OF A PILOT STUDY. Paul Nyirjesy, M.D.; Maria J.
Small, M.D.; M. Velma Weitz, M.S.N.; Paula K. Braverman, M.D.;
Steven P. Gelone, Pharm.D. Temple University School of Medi-
cine, Phildelphia, PA.
Objective: To assess the efficacy of 4% cromolyn cream in the
treatment of women with recalcitrant vulvar vestibulitis.
Study Design: The records of 7 patients who were treated with 4%
cromolyn cream for vulvar vestibulitis were reviewed. Vulvar ves-
tibulitis was diagnosed by standard criteria. Patients received 6
weeks of topical cream, applied tid to the vestibule. Analysis of
their symptoms at the end of treatment was performed.
Results: The median age was 28 years (range 23-46). Six patients
were nulliparous. The median duration of symptoms was 2.5 years
(range 0.7-6). Before treatment, mean symptom severity score was
2.7 _+ 0.5 for irritation, 1.7 +_ 1.3 for burning, 1.0 _+ 0.8 for itching,
and 2.6 ___
0.6 for dyspareunia, where a 0-3 none to severe symptom
scale was used. 4 patients had pre-existing vulvovaginal candidiasis
with persistence of symptoms despite effective antifungal treat-
ment. All patients had failed therapy with topical 0.1% triamcino-
lone ointment; 6 had failed a course of amitriptyline. After treat-
ment, all patients had no symptoms with daily activity. Dyspareunia
decreased to a score of 1.2 _+ 0.7 in the 5 patients who were sexually
active. 6 patients felt they were profoundly better; noted moderate
improvement.
Conclusions: 4% cromolyn cream may be an effective treatment
for vulvar vestibulitis. Further controlled studies will be necessary.
CUTANEOUS ANERGY IN PREGNANT AND NON-
PREGNANT WOMEN WITH HUMAN IMMUNODEFI-
CIENCY VIRUS. N.L. Eriksen, A.W. Helfgott. UTHSC--
Houston.
Objective: To determine the prevalence of cutaneous anergy in
pregnant and non pregnant women with HIV infection.
Study Design: The medical records of 159 women seropositive for
human immunodeficiency virus were reviewed. Demographic char-
acteristics and tuberculin skin test results were abstracted from the
chart. Tuberculin skin testing was performed by the Mantoux
method (5 TU of PPD) injected intradermally. Anergy testing was
performed using any two of the three following antigens; tetanus
toxoid, mumps or candida skin test antigen. A positive tuberculin
test was defined as induration of 5 mm or more and a positive
anergy test was defined as any amount of induration over the an-
ergy skin test area. A CD4+T lymphocyte count was obtained at the
time of skin testing. Continuous variables were analyzed using the
Mann Whitney-U test. Categorical data were analyzed with the
Chi-Square or Fishers’ Exact test as appropriate. A two-tailed p
value < 0.05 was considered significant.
Results: Tuberculin skin test results are shown below:
Non pregnant Pregnant
(n 102) (n 57)
Positive 13 (I 2.7%) 5 (8.7%)
Negative 62 (60.7%) 37 (64.9%)
Anergic 27 (26.6%) 15 (26.4%)
There was no significant difference in the prevalence of positive,
negative or anergic skin test results between groups. The CD4+T
lymphocyte count (mean _+ standard deviation) in patients with
anergic results was similar between pregnant (375/mm3) and non-
pregnant (358/mm3) women (p 0.64).
Conclusion: The prevalence of cutaneous anergy is similar in preg-
nant and nonpregnant women with human immunodeficiency virus.
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The CD4+T lymphocyte count was not statistically different in
pregnant versus non-pregnant women with anergy.
IMPROVED RELIABILITY OF DIAGNOSIS OF BACTE-
RIAL VAGINOSIS USING AN OBJECTIVE DEVICE FOR
DETECTION OF ELEVATED VAGINAL PH AND TRI-
METHYLAMINE. SL Hillier, J Schwebke, J Sobel. J McGregor,
RL Sweet. University of Pittsburgh, PA, University Of Alabama at
Birmingham, Birmingham, AL, Wayne State University, Detroit,
MI, University of Colorado, Denver, CO.
Objective: To evaluate interobserver reproducibility for perfor-
mance of vaginal pH and amine odor determinations, and to assess
the utility of an objective colorimetric test for vaginal pH and
trimethylamine.
Study Design: Interobserver reproducibility of pH was assessed
among 13 individuals who used pH paper to test solutions of pH
4.0-5.0. Individuals were also asked to evaluate stock solutions
containing 0.05-50.0 mM trimethylamine for amine odor in a
blinded manner. Observers evaluated a pH/amine detection card
(Fem ExamTM TestCard, Litmus Concepts, Santa Clara, CA) in the
same manner. Utility of the pH/amine detection card was Compared
to traditional pH/amine measurements in a multicenter study of 607
women.
Results: Using ColorpHast pH test strips, 23% of the observers
incorrectly identified the pH 4.5 solution as having a pH of 4.7,
while 100% of the participants correctly interpreted the pH 4.5 as
negative using the Fern ExamTM TestCard. For detection of amine
odor, only 66% of observers detected 5 mm of trimethylamine,
while 100% of observers accurately detected trimethylamine using
the colorimetric card test.
Conclusions: Traditional pH and amine testing of vaginal fluid
does not have optimal sensitivity or specificity. An objective rapid
colorimetric test for pH and trimethylamine provides better speci-
ficity for vaginal pH and improved sensitivity for trimethylamine.
These two test elements provide a rapid presumptive test for bed-
side diagnosis of BV. The clinical study demonstrated that 163
(89.6%) of 182 women positive for BV by both Gram stain and
Amsel criteria were positive for the pH/amine card test, compared
to 13 (3%) of 425 women negative for BV by Gram stain and
Amsel criteria.
ACUTE PYELONEPHRITIS: DIAGNOSTIC CRITERIA
AND CHARACTERISTICS. J.M. Piper, M.D., S.K. Zavala,
M.D., S.C. Fox, E.M-J. Xenakis, M.D., O. Langer, M.D.
Objective: To define the diagnostic criteria for acute pyelonephritis
in pregnancy, and examine the clinical characteristics.
Study Design: Consecutive pregnant women admitted tothe hos-
pital with a diagnosis of acute pyelonephritis from June 1993 to
May 1996 were analyzed. Demographic data, previous genitouri-
nary and medical history, presenting signs and symptoms, admis-
sion examination and laboratory findings, antibiotic usage and hos-
pital course were evaluated. Only cases with a positive urine culture
and fever at home or on admission were included.
Results: 126 women were admitted with acute pyelonephritis in
pregnancy over the 3-year study period (incidence 1.1%). Infection
was most common in the mid-trimester [52% vs. 19% (lst), 29%
(3rd)]. 44% had not yet sought prenatal care. This cohort was young
(35% <20 yrs, 93% <30yrs) and evenly split between multiparas
(55%) and nulliparas (45%). 37% had a prior UTI this pregnancy,
57% of which were incompletely treated.
Conclusion: CVA tenderness/Flank pain and urine bacteria/nitrites
in the presence of fever are diagnostic for pyelonephritis in preg-
nancy. Lower urinary symptoms, in contrast, are not useful for
diagnosis. Inadequate treatment of lower tract infections is a sig-
nificant contributor to development of pyelonephritis.
DETECTION OF CHLAMYDIA TRACHOMATIS ANTI-
GENIC MATERIAL IN HUMAN OVARIAN, PROSTATIC
AND SEMEN SAMPLES. Toth M, Patton DL, Campbell LA.
Dept of Obstetrics & Gynecology, Cornell University Medical Col-
lege, New York, NY, and Depts of Obstetrics & Gynecology and
Pathobiology, University of Washington, Seattle, WA, USA
Objectives: It has been hypothesized that a delayed hypersensitiv-
ity reaction in the host to chlamydial antigenic material may lead to
irreversible scarring of the reproductive tract. We used in situ hy-
bridization (ISH) and immunoperoxidase staining (IP) on human
ovarian, prostatic and semen samples to identify chlamydial anti-
genic material.
Study Design: Detection of chlamydia was achieved by two meth-
ods, IP and ISH. Tissues assessed by IP stain were labeled with one
of two antibodies. The monoclonal antibody KK12 recognizes a C
trachomatis species-specific MOMP determinant, and a separate
monoclonal antibody, CF2 which recognizes genus-specific
MOMP determinant and a separate monoclonal antibody, CF2
which recognizes genus-specific LPS. ISH detects chlamydial
DNA. Ovarian biopsy specimens from 19 culture negative women
with pelvic adhesions and/or tubal factor infertility were analyzed
by both methods. Samples of prostates from 10 men undergoing
prostatectomy for benign hypertrophy were analyzed by IP stains.
In addition, semen specimens from culture negative sexual partners
of eight women with PID and/or bacterial vaginosis were tested by
IP methods only.
Results: Seven of the 19 ovarian specimens tested positive for
chlamydia antigen or DNA (36.8%). Both chlamydial LPS and
MOMP were readily identifiable in the prostate tissues. Of the 10
hypertrophic prostates examined, 4 (40%) were positive by any
method. Of the nine samples of semen tested by IP, only one (11%)
was positive.
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Conclusions: 1. There is a high prevalence of antigenic material in
the ovaries of chronically infected, though culture negative women.
2. Chlamydia antigens may have an etiologic role in benign prostate
hypertrophy. 3. Antigenic material may be transmitted via the se-
men of culture negative men.
A RANDOMIZED CONTROLLED TRIAL OF ORAL LEVO-
FLOXACIN IN THE TREATMENT OF EXPERIMENTAL
POLYMICROBIAL PUERPERAL INFECTION IN THE
RABBIT. Leonid Reznikov, MD, Ph.D, Joan Eskens, MS, Robert
McDuffie, MD, Ronald Gibbs, MD, University of Colorado and
Kaiser Permanente, Denver, CO
Objectives: To evaluate the efficacy of oral levofloxacin in the
treatment of experimental polymicrobial puerperal infection in a
rabbit model.
Study Design: Timed pregnant rabbits on day 29-30 of a 31 day
gestation were anesthetized, and an endoscope was placed into the
vagina and advanced to the cervices, both of which were inoculated
with 105-6 c.f.u, of each of E. coli, group B streptococcus (GBS),
and Peptostreptococcus sp. Labor was induced with intramuscular
oxytocin 16 hrs. later if it had not occurred spontaneously. Does
were then observed every 3 hours for fever (>104F.). Treatment
was begun after development of fever. Animals were randomly
assigned in a blinded, placebo-controlled manner to oral levofloxa-
cin (10 mg/kg/day mixed in Nutri-Cal) or placebo (Nutri-Cal) and
treated b.i.d, for 4-5 days. Necropsy was performed 4-6 hrs after
the last dose. Cultures were taken from uterine horns, peritoneum,
and blood. Levofloxacin concentrations were determined from
blood at necropsy. Outcomes were: clinical cure of fever, eradica-
tion of microbes and presence of uterine abscesses at necropsy.
Prior to the study, a sample size was calculated. Data were analyzed
by Fisher’s exact test. A p value of <0.05 was considered signifi-
cant.
Results:
Outcome Levofloxacin Placebo p Value
Clinical cure 9/I (82%) 4/12 (33%) 0.027
Eradication of E. coli 10/I (91%) 5/12 (42%) 0.022
Eradication of GBS 5/I (45%) 4/12 (33%) 0.68
Uterine abscess 0/I 4/12 (33%) 0.09
No blood cultures were positive in any animal. Levofloxacin was
detected in all treated animals, but at low levels (<1 mcg/ml).
Conclusion: Treatment of experimental puerperal infection with
oral levofloxacin resulted in significantly more clinical cures and
eradication of E. coli compared to placebo. Sponsored by a grant
from Ortho-McNeil Pharmaceutical.
PERINATAL OUTCOME AND INFECTIOUS MORBIDITY
IN PREGNANTWOMENWHO HAVE AND HAVE NOT RE-
CEIVED PRENATAL CARE. Antonio Sison, Kristine Maxwell,
David Adler, Edward Gracley, Michael Spence
Objectives: Specific risks to which pregnant women who deliver
without prenatal care are subject have not been clearly identified.
Our goals are 1) to assess maternal and neonatal outcome and 2) to
identify risk factors in pregnancies complicated by absence of pre-
natal care when compared to an age-matched cohort who received
prenatal care in an urban inner city population.
Study Design: Outcome measures from pregnant women who pre-
sented to Labor and Delivery with no prenatal care (NPC group)
were collected from 1993 through 1996. Data on maternal history
and outcome were recorded and then compared with an age-
matched, parity-matched control group who received prenatal care
(PNC group) in an inner city resident-run clinic. Drug abuse re-
ferred to crack-cocaine but also included heroine, cannabis, pency-
clidine, and ethanol.
Results:
NPC group PNC group
(n 234) (n 95)
History of drug abuse 165 (71%) 25 (26%), p<0.001
History of STD’s 102 (44%) 45 (47%)
Gestational age at delivery 34.8 weeks 38.5 weeks
Preterm deliveries
(<37 weeks) 138(59%) 16 (17%), p<0.001
Type of delivery:
Vaginal 158 (87%) 80 (85%)
Operative vaginal 9 (5%) 3 (3%)
Cesarean 15 (8%) 12 (I 2%)
Hospital length of stay 2.05 days 1.85 days
Positive urine drug screen 126 (54%) N/A
Reactive test to syphilis 40 (I 7%) 4 (4%), p<0.01
Mean birth weight 2491 grams 3158 grams
Apgars scores
(<5 at min or
<7 at 5 mins) 79 (34%) 16 (I 7%), p<0.01
Conclusions: 1) When compared to the PNC group, the NPC group
were at risk for having a maternal history of drug abuse, earlier
gestational age at delivery, higher preterm delivery rates, reactivity
to the syphilis test, and lower apgar scores, 2) lack or absence of
prenatal care did not appear to affect the cesarean section rate or the
maternal hospital length of stay, and 3) more than half of the NPC
patients presented to Labor and Delivery with a positive urine drug
screen, the majority of which was for cocaine metabolites.
THE EFFECTS OF ESCHERICHIA COLI HEAT-STABLE
(STa) TOXIN OVER HUMAN MYOMETRIUM CONTRAC-
TILITY "IN VITRO". Carrera-Leal, B Leal de Carrera, A Pier-
dant PG, Deleon DF.
Objective: The purpose of the study was to assess the effects of
Escherichia coli heat stable (STa) toxin on isolated human myo-
metrium response to oxytocin. Method: 116 muscle strips were
obtained from the lower uterine segment of 42 women undergoing
Cesarean section. Uterine response to oxytocin was recorded before
and after the incubation with this toxin. A pD for strips with and
without spontaneous activity in response to oxytocin before and
after the incubation with STa toxin or vehicle was calculated. A
paired T test was used for comparison.
Results: Muscle strips with and without spontaneous activity re-
sponded to cumulative doses of oxytocin before and after the in-
cubation with STa toxin or vehicle. No differences in contractility
were noted in between the groups (p < 0.05). Furthermore, this
toxin was not able to induce uterine contractility when tested alone.
Conclusions: The inability of this toxin to affect myometrium re-
sponse to oxytocin may be due to the lack of amnion cells or the
absence of STa receptors in this tissue.
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WOMEN UNDERGOING CESAREAN FOR GENITAL
HERPES LESIONS. L.M. Hollier, D. Dawson, L.L. Scott, and
G.D. Wendel, Dept. Ob/Gyn, Univ. TX Southwestern Med. Ctr.,
Dallas, TX
Objectives: To determine the rate of herpes virus recovery from
cultures taken at delivery and the frequency of puerperal endome-
tritis in women delivered by cesarean section for symptomatic geni-
tal herpes.
Study Design: Retrospective chart review of women undergoing
cesarean delivery for genital lesions between 1/1/88 and 12/31/95 at
Parkland Memorial Hospital. Cultures of the cervix, active lesion
site, and usual lesion site were taken prior to cesarean delivery.
Cultures were performed by the Virology Lab at the University of
Texas Southwestern Medical Center. Women taking acyclovir at
delivery were excluded.
Results: Study criteria were met by 197 women.
st Episode Recurrent
(N 84) (N II 3)
Positive delivery culture 26/60 (43%) 27/7 (40%)
Lesion duration
Positive culture 4.2 days 3.0 days
Negative culture 5.4 days 4.5 days
Endometritis 19/84 (23%) 20/I 13 (18%)
Fourteen women were having prodromal symptoms alone at deliv-
ery. None had a positive culture. No infants in this cohort devel-
oped neonatal herpes (attack rate 0.00 (95% CI, 0.00-1.86). Only
one infant had a positive culture; he exhibited no clinical disease.
Conclusions: Viable virus was recovered from a higher percentage
of our patients with recurrent disease than is generally reported.
Endometritis complicates the postpartum course of 20%’ of women
undergoing cesarean for symptomatic genital herpes.
MATERNAL SERUM GRANULOCYTE COLONY STIMU-
LATING FACTOR (G-CSF) CONCENTRATIONS IN PRE-
TERM PREMATURE RUPTURE OF MEMBRANES
(PPROM) AND CHORIOAMNIONITIS. AP Murtha MD, KA
Boggess MD, and PC Greig MD. Duke University Medical Center,
Department of OB/Gyn, Durham, NC.
Objective: Preterm birth has been linked with intrauterine infection
and inflammation. Serum and amniotic fluid markers of inflamma-
tion have been associated with clinical and subclinical chorioam-
nionitis and preterm delivery. This study was designed to determine
if maternal serum G-CSF levels are elevated in patients with
PPROM and intrauterine infection.
Study Design: Maternal serum samples were obtained from 21
patients with PPROM at 22-34 weeks gestation on the day of
delivery. Maternal serum G-CSF concentrations were determined
using a specific ELISA kit (R&D Systems, Inc). Clinical and his-
tologic chorioamnionitis were defined by standard criteria. Statis-
tical analysis was by Mann Whitney U test.
Results: Of the 21 PPROM patients, 13 (62%) had clinical evi-
dence of infection on the day of delivery. Maternal serum G-CSF
concentrations were significantly higher when clinical chorioamni-
onitis was present compared to those without clinical chorioamni-
onitis (146 vs 56 pg/ml, p .026). Placental pathology was avail-
able in 20 patients. Histologic chorioamnionitis was present in 19
patients, of these, 8 (42%) were without clinical evidence of infec-
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tion. Serum G-CSF concentrations were significantly higher in
PPROM patients with clinical and histologic chorioamnionitis
when compared to those with histologic chorioamnionitis alone
(126 vs 36 pg/ml, p .035).
Conclusions: Intrauterine infection causes a local inflammatory
response resulting in the production of various mediators, including
G-CSF. The systemic release of G-CSF is more pronounced in
PPROM patients with clinical chorioamnionitis, suggesting that
G-CSF may not be an early mediator in subclinical infection in
patients with PPROM.
A COST EFFECTIVENESS EVALUATION OF INPATIENT
PELVIC INFLAMMATORY DISEASE TREATMENT.
Mazzoni MM, Ransom SB, Hendrix SL, McNeeley SG. Division of
Gynecology, Wayne State University/Hutzel Hospital, Detroit,
Michigan.
Objective: To determine the most cost effective antibiotic regimen
for treating inpatient pelvic inflammatory disease in an urban, uni-
versity-affiliated, teaching hospital.
Study Design: A retrospective evaluation for the treatment of in-
patient pelvic inflammatory disease was completed. Admission was
based on clinical criteria of significant leukocytosis, fever, sus-
pected tubo-ovarian abscess (TOA), or recent outpatient treatment
failure that were felt to warrant parenteral antibiotic therapy. The
patients were prescribed one of three treatment options including
Gentamicin/Clindamycin (with or without Ampicillin) and Ce-
fotetan/Doxcycline. The patients were evaluated daily by a physi-
cian with treatment failures determined by failure to respond to the
initial antibiotic regimen or clinical deterioration. Treatment fail-
ures had alternative antibiotic regimens completed. A formal cost
analysis of the treatment options was completed.
Results: The treatment outcome for patients with pelvic inflamma-
tory disease without tubo-ovarian abscess was found to be similar
with either antibiotic treatment option. However, the daily cost of
the chosen antibiotic therapy varied significantly. Treatment fail-
ures were most strongly associated with the presence of TOA.
Patients with TOA were found to have a significantly shorter hos-
pital stay when treated with Ampicillin/Gentamicin/Clindamycin
when compared with Gentamicin/Clindamycin alone or Cefotetan/
Doxcycline.
Conclusion: As concerns for cost-effective inpatient clinical care
escalate, given equivalent outcomes for treatment of PID without
TOA, the most cost effective antibiotic regimens should be chosen.
In patients with TOA, triple therapy with Ampicillin/Gentamicin/
Clindamycin proved to be more effective and therefore more cost-
effective for treatment.
COST EFFECTIVENESS OF DOXYCYCLINE VERSUS
AZITHROMYCIN IN THE TREATMENT OF CHLAMYDIA
TRACHOMATIS INFECTIONS OF THE CERVIX.
Ransom, SB, McNeeley SG, Mazzoni M, Hendrix S. Division
of Gynecology, Wayne State University School of Medicine, De-
troit, MI
Objective: As concerns of cost effective treatment gains impor-
tance, clinical providers must be knowledgeable regarding the most
clinically effective treatment modality for common disorders. This
research was designed to compare the cost-effectiveness of doxy-
cycline versus azithromycin in the treatment of chlamydial infec-
tions of the cervix.
Study Design: Sixty consecutive patients with Chlamydia tracho-
matis genital infections were randomly assigned to treatment with
azithromycin, one gram po or doxycycline, 100mg BID for seven
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days. Study patients were aged 18-30 years without any other
medical problems. Patients received outpatient therapy and re-
turned 3 weeks after completion for re-evaluation. During the treat-
ment period through re-evaluation, the patients refrained from coi-
tus, avoided alcohol and drugs, and all other medications. The
patients were tested with a DNA probe for Chlamydia trachomatis.
The patients were randomized by a nurse and were blinded for
study purposes to the evaluating physician.
Results: Chlamydial infection cure rates were not significantly dif-
ferent between the two groups [azithromycin (29/30) and doxycy-
cline (25/30)]. No significant complications were found in either
treatment group. The complete clinic cost for treatment was $26.15
for azithromycin and $6.50 for doxycycline.
Conclusion: The most cost-effective treatment for genital chla-
mydial infections in this small study appeared to be doxycycline.
However, while treatment with azithromycin was significantly
more expensive than doxycycline, there were slightly fewer treat-
ment failures.
CHLAMYDIA TRACHOMATIS IN PREGNANCY: PREVA-
LENCE, RISK FACTORS, AND PREGNANCY OUTCOME.
Renee Fogelberg, MD, David Robin Field MD, Ira Golditch MD,
Howard Barkin, Ph.D.
Objectives: This study looks at the prevalence of chlamydia in the
population of pregnant females who receive prenatal care and de-
liver at Kaiser Permanente Medical Center, San Francisco. Risk
factors for positive testing are outlined. Specific risk factors ana-
lyzed include: age, ethnicity, maternal occupation, marital status,
and past history of sexually transmitted disease. Pregnancy out-
comes (gestational age, weight, and infectious morbidities) related
to positive cultures are profiled.
Study Design: A retrospective population based cohort study of
1255 women who received a chlamydia screen in their pregnancy,
between November 1994 and June 1996. Epidemiologic ’and preg-
nancy outcome data are collected by chart review. Positive screens
are detected by enzyme-immunoassay (EIA) based methods.
Results: Chlamydia is identified in less than 5% of this patient
population. 68% of patients have a single screening test. No statis-
tically significant difference is noted in poor pregnancy outcomes
(low birth weight, and gestation age less than 37 weeks) for those
patients who are screen-positive for chlamydia.
Conclusion: This study reflects a unique population that have most
of their screening tests during the first trimester. The low preva-
lence rate of disease makes it difficult to note a significant impact
on pregnancy outcome. It is not known whether these infections
represent a chronic disease state, which might have less effect on a
given pregnancy. The inherent limitations of a retrospective, non-
case controlled study, which did not control for other infectious
pathogens is noted.
References: Gravett MG, Nelson HP, et al: Independent associa-
tion of bacterial vaginosis and chlamydia trachomatis infection with
adverse pregnancy outcome. JAMA 1986; 256:1899-1903.
Sweet RL, Landers DV: Chlamydia trachomatis infection and preg-
nancy outcome. AM Obstet Gynecol 1987; 156:824-33.
EXPERIMENTAL MODEL OF NEONATAL GONOCOC-
CAL INFECTION, TRANSMISSION OF N. GONORRHoEAE
FROM PREGNANT MOTHER TO THE FETUS IS Clq DE-
PENDENT. Stella Nowicki, D.D.S. ,2 and Bogdan Nowicki, M.D.,
Ph.D. ,2. Departments of Ob/Gyn & Microbiology2, University of
Texas Medical Branch, Galveston, Texas.
Gonorrhea in pregnant women is associated with increased risks of
spontaneous abortion and perinatal infant mortality, but is uncertain
whether gonococcal infection is directly responsible for these com-
plications or is a marker of high risk pregnancy due to other patho-
genic mechanisms.
Objectives: The purpose of this investigation was to evaluate the
effects of gonococcal infection during pregnancy on neonatal out-
comes.
Study Design: Rats in day 20 of pregnancy were infected by in-
traperitoneal inoculation (i.p.) with three different N. gonorrhoeae
strains originating from patients with: pelvic inflammatory disease
(PID), disseminated gonococcal infection (DGI) and local infection
(LI). Each group was divided into two subgroups: inoculated with
5 x 107 N. gonorrhoeae pretreated with Clq or without C lq. The
study included 65 pregnant rats total. Blood samples were collected
from pregnant and neonatal rats 48 h postinoculation and cultured
on modified Thayer-Martin agar plates in triplicate for 24h in COz
incubator.
Results: The blood cultures of all 60 pregnant rats were negative.
Interestingly, blood cultures of neonates were positive in two sub-
groups inoculated with PID and DGI strain pretreated with human
C q, but not in groups without C q treatment. Results showed that
experimental infection during pregnancy with PID and DGI but not
LI strains of N. gonorrhoeae resulted in developing neonatal bac-
teremia in the presence of human factor C q.
Conclusions: Neonatal gonococcal infection was highly correlated
with perinatal infant morbidity (68%) and mortality (30%). We
conclude that C q dependent experimental gonococcal infection of
pregnant rats may be relevant for evaluation of pathogenesis of
neonatal bacteremia and associated complications.
COST EFFECTIVENESS EVALUATION OF METRONIDA-
ZOLE VERSES METROGEL VAGINAL(R) IN THE TREAT-
MENT OF BACTERIAL VAGINOSIS. Ransom, SB, McNeeley
SG, Mazzoni M, Hendrix S. Division of Gynecology, Wayne State
University School of Medicine, Detroit, MI
Objective: As managed care and concern of cost effectiveness
expands, clinical providers must be knowledgeable regarding the
most clinically efficient treatment modality for common disorders.
This research was designed to compare the cost-effectiveness of
metronidazole verses Metrogel Vaginal(R) in the treatment of bacte-
rial vaginosis.
Study Design: 60 consecutive patients with the clinical diagnosis
of bacterial vaginosis were randomly assigned prospectively into
either a metronidazole (500mg BID x 7d) or Metrogel Vaginal
(R)
(one applicator BIS x 5d) treatment group. The study patients were
aged 18-30 years without any other medical problems. The patients
proceeded with outpatient therapy and returned 7-10 days after the
completion of treatment for reevaluation. During the study, the
patients refrained from sexual relations, avoided alcohol and drugs,
and avoided all other medications. The physician evaluated the
patients for bacterial vaginosis through standard wet prep, whiff test
and pH testing prior to and after treatment. The patients were ran-
domized by a nurse and were blinded for study purposes to the
evaluating physician.
Results: The successful treatment outcomes for bacterial vaginosis
was found to be 27 and 28 patients for Metrogel Vaginal
(R) and
metronidazole, respectively, out of the original 30 patients in each
study group. All patients introduced into the study completed the
study without difficulty. No significant complications were found
in either treatment group. Three patients treated with metronidazole
experienced Nausea during the treatment interval. The entire cost
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 363for treatment was $19.71 and $1.51 for Metrogel Vaginal(R) and
metronidazole, respectively.
Conclusion: The most cost-effective treatment for bacterial vagi-
nosis was found to be generic metronidazole. While the use of the
more expensive Metrogel Vaginal
(R) may be reasonable for patients
experiencing side effects of metronidazole, most patients should be
treated with the less expensive metronidazole.
INTEGRATION OF IN VITRO SUSCEPTIBILITY MIC
ACTIVITY OF TROVAFLOXACIN AGAINST ANAER-
OBES WITH HUMAN PHARMACOKINETIC DATA.
Kenneth E. Aldridge, Ph.D
Trovafloxacin is a new fluoroquinolone with broad-spectrum anti-
bacterial activity which includes aerobic gram-positive cocci and
anaerobes. Animal models indicate that there is a positive correla-
tion between the bacteriologic eradication of organisms and the
ratio of antibiotic concentration to in vitro MIC values. This study
integrated in vitro susceptibility data of trovafloxacin against an-
aerobes with pharmacokinetic data to give trafloxacin: MIC ratios
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and to determine the time the trovafloxacin concentration was
above the MIC. Comparisons were based on a 300 mg dose of
trovafloxacin which yielded a plasma Cmax-4.3 Ig/ml which was
divided by the mode MIC (T/mm) and MIC9o (T/M90). Time above
the MIC’ (hrs: T > MM; T > M90 was determined from the plasma
profile of trovafloxacin over 48 hrs. Among the various species of
the B. fragilis group the T/MM ranged from 8.6 to 34.4 and the T
> MM ranged from 29 to 36 hrs. With the exception of B. vulgatus
the T/M90 ranged from 4.3 to 8.6 and the T > MIC9o ranged from
12 to 29 hrs. For other anaerobic gram-negative bacilli (Prevotella,
Porphyromonas, Fusobacterium) the values were T/MM-8.6 to
17.2, T > MM-29 to 36 hrs, T/MIC9o-4.3 to 8.6, and T > M90-4.3
to 8.6 hrs. For isolates of Clostridium, Eubacterium, Peptostrepto-
coccus, and Veillomella the values were T/MM-34.4 to 137.6, T >
MM- > 36 hr., T/M90-8.6 to 17.2, and T > M90-29 to > 36 hrs.
These data indicate that a single 300 mg dose of trovafloxacin
produces favorable ratios to predict efficacy against these clinically
significant pathogens. Moreover, trovafloxacin is highly tissue con-
centrated and when these data are available for the uterus and
vagina ratios are also expected to be highly favorable.
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